Mostrar registro simples

dc.contributor.authorFrank, Luiza Abrahãopt_BR
dc.contributor.authorSandri, Giuseppinapt_BR
dc.contributor.authorD'Autilia, Francescapt_BR
dc.contributor.authorContri, Renata Vidorpt_BR
dc.contributor.authorBonferoni, Maria Cristinapt_BR
dc.contributor.authorCaramella, Carlapt_BR
dc.contributor.authorFrank, Alejandro Germánpt_BR
dc.contributor.authorPohlmann, Adriana Raffinpt_BR
dc.contributor.authorGuterres, Silvia Stanisçuaskipt_BR
dc.date.accessioned2014-09-19T02:14:48Zpt_BR
dc.date.issued2014pt_BR
dc.identifier.issn1178-2013pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/103469pt_BR
dc.description.abstractThe vaginal route of administration is an alternative for several treatments for either local or systemic pharmacological effects. However, the permanence of a drug in this route represents a challenge for formulation development that can be overcome by using nanoencapsulation and chitosan gel. Thus, this work aimed to evaluate the performance of chitosan hydrogels containing cationic and anionic acrylic-based nanocapsules (Eudragit® RS 100 and Eudragit® S 100, respectively) with Nile red as a model of lipophilic substance in the vaginal route of administration, as measured by increases in the residence time and the penetration of these formulations. Several formulations were prepared with increasing chitosan concentrations, and were analyzed in terms of pH and rheological behavior so that the most suitable formulation could be selected. The enhancement of the adhesion (tensile stress test and washability profile) and penetration (confocal laser scanning microscopy and extraction followed by quantification) properties of the formulations, when applied to porcine vaginal mucosa, were evaluated. The nanocapsule suspensions produced presented adequate properties: size of approximately 200 nm (polydispersity index of≤0.2); zeta potential around +10 mV for the cationic formulation and -10 mV for the anionic formulation; and pH values of 6.1±0.1 (Eudragit RS 100), 5.3±0.2 (Eudragit S 100), 6.2±0.1 (Nile red loaded Eudragit RS 100), and 5.1±0.1 (Nile red loaded Eudragit S 100). The chitosan formulation presented suitable viscosity for vaginal application and acidic pH (approximately 4.5). The tensile stress test showed that both formulations containing polymeric nanocapsules presented higher mucoadhesion when compared with the formulation without nanocapsules. In the washability experiment, no significant differences were found between formulations. Confocal microscopy and fluorescence quantification after extraction from the mucosa showed higher penetration of Nile red when it was nanoencapsulated, particularly in cationic nanocapsules. The formulations developed based on chitosan gel vehicle at 2.5% weight/weight containing polymeric nanocapsules, especially the cationic nanocapsules, demonstrated applicability for the vaginal delivery of hydrophobic substances.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofInternational Journal of Nanomedicine. Auckland. Vol. 9, no. 1 (July 2014), p. 3151-3161pt_BR
dc.rightsOpen Accessen
dc.subjectQuitosanapt_BR
dc.subjectEudragit® RS 100en
dc.subjectEudragit® S 100en
dc.subjectNanotecnologiapt_BR
dc.subjectNanocápsulas poliméricaspt_BR
dc.subjectVaginal routeen
dc.subjectNanotechnologyen
dc.titleChitosan gel containing polymeric nanocapsules : a new formulation for vaginal drug deliverypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000922201pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples